Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.46 USD
+0.15 (0.57%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $26.44 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Industry / Sector Report
Industry : Medical - Biomedical and Genetics
Zacks Industry Rank
Top 33% (83 out of 251)Zacks Sector Rank
Top 31% (5 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.55 | 1.37 | 9.99 |
Current Quarter Estimate | 0.42 | 3.10 | 61.00 |
Year Ago Quarter Estimate | 0.10 | -4.81 | 54.84 |
Next Quarter Estimate | 0.41 | 3.85 | 63.00 |
Next Year Estimate | 1.85 | 24.86 | 275.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 98.89 | 17.20 | 15.67 |
Next Year | 3.35 | 9.80 | 11.34 |
Last 5 Years | -8.10 | 0.90 | 8.10 |
Next 5 Years | 29.80 | 21.80 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | 18.38 | -6.44 |
Price/Book (MRQ) | 3.56 | 1.97 |
Price/Cash Flow (MRFY) | 34.36 | 16.43 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | 17.38% | -152.35% |
Return on Equity (TTM) | 15.54% | -60.91% |
Debt to Equity (MRQ) | 0.00 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.